Phase I Trial Of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in Patients With Locoregionally Advanced Head and Neck Carcinoma

Trial Profile

Phase I Trial Of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in Patients With Locoregionally Advanced Head and Neck Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs GL ONC1 (Primary) ; Cisplatin
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Nasopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer; Salivary gland cancer
  • Focus Adverse reactions
  • Sponsors Genelux Corporation
  • Most Recent Events

    • 05 Jul 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top